Colorectal Cancer Diagnostics Market: as blood-based primary screening achieves FDA approval and immediate Medicare coverage, the decade-long monopoly of stool and colonoscopy testing on guideline-recommended colorectal cancer screening ends, so more than 45 million Medicare beneficiaries gain access to a non-invasive blood draw alternative for the first time, and demand concentrates on platforms that can scale laboratory capacity to serve a population that has historically declined or deferred all existing screening options.

The global colorectal cancer diagnostics market size was USD 6.30 Billion in 2025 and is expected to register a revenue CAGR of 11.2% during the forecast period. Market revenue growth is driven by factors such as FDA approval of blood-based primary colorectal cancer screening, established stool DNA platform scale generating repeat testing volume, and accelerating molecular residual disease monitoring adoption across oncology practices. The first driving factor is the FDA approval on July 29, 2024 of the Shield blood test for primary colorectal cancer screening in adults aged 45 and older at average risk, making it the first blood test approved as a primary screening option and the first to meet the requirements for Medicare coverage under CMS National Coverage Determination 210.3, immediately making blood-based screening accessible to more than 45 million Medicare beneficiaries and removing the regulatory and reimbursement barriers that had previously confined blood-based testing to a niche cash-pay category. The second driving factor is the scale and commercial infrastructure of the established stool DNA testing platform, with Cologuard having been used to screen for colorectal cancer 18 million times since its 2014 launch and Exact Sciences reporting total 2024 revenue of USD 2.76 Billion driven primarily by Screening revenue of USD 2.10 Billion, demonstrating that stool-based testing generates a durable, high-volume recurring testing base that sustains market revenue independent of the blood-based screening growth trajectory. The third driving factor is expanding adoption of molecular residual disease monitoring tests that track cancer recurrence in patients following curative-intent treatment, with Exact Sciences confirming peer-reviewed journal acceptance for the first publication on its Oncodetect MRD test, opening a new post-treatment testing category that extends colorectal cancer diagnostics revenue beyond the initial screening encounter into multi-year recurrence surveillance. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way approved non-invasive screening platforms accumulate clinical outcome data and guideline endorsements over time, which allows each additional endorsement to expand the ordering physician base without requiring a new commercial sales investment at each clinic. Once a platform achieves guideline inclusion and Medicare coverage, each subsequent guideline body endorsement adds a new ordering context and payer category that was previously closed, so the commercial addressability of the platform compounds in scope as it accumulates institutional endorsements across different clinical societies, payer types, and care settings. As a result, demand and revenue share are concentrating around platforms with multi-guideline endorsement and established laboratory infrastructure, and the forecast tilts toward these multi-endorsed platforms rather than single-study newcomers that have not yet navigated the guideline inclusion cycle. For instance, in November 2024, Exact Sciences presented data on its competing blood-based colorectal cancer screening test showing 88% sensitivity for colorectal cancer and 31% sensitivity for advanced precancerous lesions at 90% specificity, one of more than a dozen clinical data readouts the company generated across its screening, precision oncology, and MRD portfolio in a single year to accelerate guideline consideration across multiple clinical societies simultaneously. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the FDA's approval of the Shield blood test on July 29, 2024 for colorectal cancer screening in adults aged 45 and older at average risk, establishing blood-based testing as a guideline-equivalent primary screening option for the first time in the history of colorectal cancer diagnostics. Blood-based screening works only if it can achieve guideline inclusion and payer coverage, and Shield's approval was specifically based on the ECLIPSE registrational trial of more than 20,000 average-risk adults conducted across more than 200 clinical trial sites in 37 states, demonstrating 83% sensitivity for colorectal cancer detection with 90% specificity for advanced neoplasia. More than 45 million Medicare beneficiaries gained access to the blood-based screening option immediately upon commercial launch in August 2024 under CMS National Coverage Determination 210.3, and since the commercial introduction of the laboratory-developed test version of Shield in May 2022 the overall patient adherence rate has exceeded 90%. In January 2026, the American College of Gastroenterology updated its colorectal cancer screening guideline recommendations to include blood-based testing as a category-equivalent option alongside stool-based and colonoscopy-based methods, removing the remaining clinical positioning ambiguity that had required physicians to characterise blood-based testing as a secondary or supplemental choice. The effect on the market is that the removal of both regulatory and reimbursement barriers creates a step-change expansion in the total addressable market for non-invasive screening by converting the approximately 37% of screening-eligible Medicare beneficiaries who have never completed any recommended screening into a commercially reachable population for the first time. These are some of the key factors driving revenue growth of the market.

The second driver is the commercial maturation of the stool DNA testing platform and the imminence of a second blood-based screening platform from Exact Sciences, which together establish that the colorectal cancer non-invasive screening market is moving from a single dominant platform to a multi-platform testing landscape that will expand overall testing volume. Exact Sciences reported Screening revenue of USD 2.10 Billion in FY2024 primarily from Cologuard laboratory service revenue, with the test having achieved 18 million cumulative screenings since its 2014 launch across adults 45 years and older at average risk, and CEO Kevin Conroy describing 2025 as positioned to be the most productive year in company history due to continued Cologuard penetration and planned new product launches. Exact Sciences presented data in November 2024 showing its own blood-based colorectal cancer screening test achieved 88% sensitivity for colorectal cancer and 31% sensitivity for advanced precancerous lesions at 90% specificity, outperforming Shield's 83% cancer sensitivity and positioning Exact Sciences to compete directly with Guardant Health for Medicare screening volume. The company also confirmed peer-reviewed journal acceptance for the first publication on its Oncodetect molecular residual disease and recurrence monitoring test in November 2024, expanding the company's commercial addressability beyond the initial screening encounter into multi-year post-treatment surveillance. The effect on the market is that two well-capitalised companies with established laboratory infrastructure and Medicare relationships competing for the same unscreened Medicare population creates a sustained period of test volume growth that does not depend on one company winning market share from the other but rather on both expanding the overall screening completion rate among previously untested beneficiaries. These are some of the key factors driving revenue growth of the market.

Guardant Health's Shield blood test achieved greater than 90% patient adherence in real-world clinical use since its laboratory-developed test launch in May 2022. The July 2024 FDA approval and immediate CMS Medicare coverage extends this adherence rate advantage to more than 45 million Medicare beneficiaries and establishes blood-based primary colorectal cancer screening as a reimbursed clinical standard rather than a cash-pay option for the first time.

The third driver is the emerging category of molecular residual disease monitoring tests that detect trace levels of tumor-derived circulating tumor DNA in patient blood samples following colorectal cancer treatment, providing oncologists with an early indication of disease recurrence before it becomes clinically detectable through imaging or symptom presentation. MRD monitoring works through the detection of patient-specific tumor somatic variants in serial blood draws at defined surveillance intervals, and each patient who completes curative-intent colorectal cancer treatment becomes a recurring testing customer for 5 or more years of post-treatment surveillance, so the commercial model is substantially more recurring than a single screening episode. Exact Sciences confirmed peer-reviewed journal acceptance for the first publication on its Oncodetect MRD test, and Natera's Signatera ctDNA monitoring platform has accumulated an established evidence base across multiple cancer types including colorectal cancer with published data supporting its use in post-surgical residual disease detection and recurrence monitoring in patients receiving adjuvant chemotherapy. In 2025, multiple major academic cancer centres including those affiliated with the National Comprehensive Cancer Network formally incorporated ctDNA MRD monitoring into colorectal cancer post-treatment follow-up protocol frameworks, creating institutional ordering pathways for MRD testing independent of commercial payer reimbursement decisions. The effect on the market is that MRD monitoring creates a high-value recurring revenue stream per colorectal cancer patient that is structurally separate from, and additive to, the population screening revenue generated by Cologuard and Shield, expanding the total colorectal cancer diagnostics market beyond the screened-population addressable market into the treated-and-surveilled patient population. These are some of the key factors driving revenue growth of the market.

However, the colorectal cancer diagnostics market faces adoption constraints from the persistent screening completion gap that remains structurally resistant to new testing option availability. Because more than three out of four individuals who die from colorectal cancer were not up to date with their screening despite Cologuard, FIT testing, and now Shield all being commercially available and broadly insured, the underlying barrier is a healthcare access, awareness, and engagement problem that does not resolve automatically when a more convenient testing modality is approved, so the unscreened population requires active outreach investment that generates costs not fully recovered from per-test reimbursement rates at current Medicare pricing for blood-based screening. Sensitivity positioning is a second constraint, because Shield demonstrated 83% sensitivity for colorectal cancer detection, within the guideline-acceptable range but materially below colonoscopy sensitivity, requiring careful and sustained physician communication that a negative blood test result does not eliminate the recommendation for follow-up colonoscopy at guideline-recommended intervals, and any positioning of the blood test as a colonoscopy substitute creates regulatory and liability risk for ordering physicians. International reimbursement variability is the third constraint, since outside the United States the CMS NCD 210.3 framework has no equivalent national coverage decision in any major market, so blood-based and advanced stool-based screening technologies face uneven, country-by-country market entry challenges that constrain the geographic diversification of colorectal cancer diagnostics revenue away from the US Medicare base over the 2026 to 2030 period. These factors substantially limit colorectal cancer diagnostics market growth over the forecast period.

Based on test type, the global colorectal cancer diagnostics market is segmented into stool DNA and immunochemical tests, blood-based liquid biopsy tests, colonoscopy and biopsy diagnostics, and molecular residual disease tests. Stool DNA and immunochemical tests hold the largest revenue share, because Cologuard combines multi-target stool DNA with a fecal immunochemical test component detecting altered DNA biomarkers and hemoglobin in a single at-home collection kit that patients mail to a laboratory, providing a non-invasive alternative to colonoscopy with 18 million cumulative tests since 2014 and both American Cancer Society and US Preventive Services Task Force guideline endorsement, which suits the primary care screening referral model of high-volume ordering across a broad population. Blood-based liquid biopsy tests are expected to register the most rapid revenue growth rate in the global colorectal cancer diagnostics market over the forecast period, driven directly by the FDA approval of Guardant Health's Shield in July 2024 and Exact Sciences' competing blood-based test in active clinical development following its November 2024 data presentation, which is why both companies are simultaneously investing in direct-to-consumer awareness campaigns targeting the approximately 45 million previously unscreened Medicare beneficiaries.

Based on end-use, the global colorectal cancer diagnostics market is segmented into hospitals and clinics, reference and independent laboratories, home and self-collection settings, and cancer centres and oncology practices. Hospitals and clinics hold the largest revenue share, representing the primary point of screening test ordering by primary care physicians and gastroenterologists managing the colorectal cancer screening referral pathway for average-risk patients reaching age 45, supported by the integration of electronic health record-based screening reminders that generate consistent ordering volume from the age-eligible Medicare population. Home and self-collection settings are expected to register the fastest revenue growth rate in the global colorectal cancer diagnostics market over the forecast period, driven by Cologuard's established at-home stool collection model and the simple venous blood draw collection process for Shield that can be completed during a routine primary care office visit, which is why both Exact Sciences and Guardant Health are investing in patient-initiated self-scheduling and home collection logistics infrastructure to lower the completion barrier for previously unscreened populations.

Based on technology, the global colorectal cancer diagnostics market is segmented into DNA methylation and multi-target testing, circulating tumor DNA testing, and other molecular technologies. DNA methylation and multi-target testing holds the largest revenue share through the established Cologuard platform, which combines multiple DNA methylation biomarkers with hemoglobin immunochemical detection in a single integrated test result that has achieved the broadest US guideline endorsement of any non-invasive colorectal cancer screening modality. Circulating tumor DNA testing is expected to register the most rapid revenue growth rate in the global colorectal cancer diagnostics market over the forecast period, driven by the Shield blood test's detection of cell-free DNA methylation signatures shed by colorectal tumors into the bloodstream and by the broader application of ctDNA technology to molecular residual disease monitoring following treatment, which is why Guardant Health and Natera are both investing in companion diagnostic indication expansions and post-treatment ctDNA surveillance protocols at major US academic cancer centres.

Based on regional analysis, the colorectal cancer diagnostics market in North America accounted for largest revenue share in 2025. The United States drives the regional position through the combination of the FDA approval and immediate CMS Medicare coverage of the Shield blood test, the established Cologuard commercial infrastructure with 18 million cumulative tests since 2014, and a colorectal cancer disease burden that the American Cancer Society estimates at more than 150,000 new diagnoses annually with more than 53,000 attributable deaths. Exact Sciences, headquartered in Madison, Wisconsin, confirmed that Cologuard generated USD 2.10 Billion in Screening revenue in FY2024, representing approximately 33% of the total colorectal cancer diagnostics market by revenue in a single year from a single platform, a concentration that reflects North America's dominant market position in stool-based screening infrastructure. The concentration of the FDA companion diagnostic approval pathway, the CMS NCD 210.3 reimbursement framework, and both major non-invasive screening platform headquarters in the United States also means that new colorectal cancer diagnostic technologies, including next-generation blood-based tests and MRD monitoring platforms, are launched and achieve commercial scale in the United States first before international regulatory submissions.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national colorectal cancer diagnostics markets within Europe, with several national health systems operating organised colorectal cancer screening programmes based primarily on fecal immunochemical testing followed by colonoscopy referral for positive results, a well-established but lower-revenue-per-test screening model than the stool DNA platform dominant in North America. The European CE-IVDR regulatory framework creates a distinct approval pathway for blood-based and stool DNA screening tests that requires independent performance evidence for each European launch, extending the timeline before US-approved screening platforms can access European reimbursement, and individual national screening programme administration decisions determine whether new testing modalities can enter organised programme protocols. The result is steady rather than rapid growth, shaped more by organised screening programme policy decisions and CE-IVDR regulatory timelines than by commercial launch velocity.

The market in Asia Pacific is expected to register the fastest revenue growth rate over the forecast period. Japan, China, and South Korea represent the three largest national colorectal cancer diagnostics markets within the region, driven by high and rising colorectal cancer incidence rates and expanding organised fecal immunochemical testing screening programmes. Japan's colorectal cancer incidence ranks among the highest globally per capita, sustaining high-volume organised population screening that generates consistent FIT testing revenue, and South Korea's National Cancer Screening Programme covers colorectal cancer with annual FIT testing for eligible adults, creating an established national testing infrastructure that supports market expansion for new testing modalities as they achieve Korean regulatory clearance. The breadth of unmet screening need across the Asia Pacific region, combined with the relatively lower penetration of advanced stool DNA and blood-based platforms outside the Japan and South Korea installed base, leaves more room for growth than in North America or Europe.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national colorectal cancer diagnostics markets in the region, with access concentrating in private specialist oncology and gastroenterology practices in Sao Paulo, Mexico City, and other major urban centres where patients can access stool DNA and blood-based testing through out-of-pocket payment or private insurance. Public health screening programmes in Latin America are predominantly limited to conventional fecal occult blood testing given cost constraints, and the indirect effects of Iran-US sanctions on South American freight routes have maintained elevated import costs for specialty molecular diagnostic reagents and laboratory consumables reaching Brazilian and Mexican clinical testing sites through 2026, further constraining affordable access to advanced colorectal cancer diagnostic platforms beyond the urban private healthcare sector.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the United Arab Emirates represent the primary commercial colorectal cancer diagnostics markets within the region, supported by government investment in comprehensive oncology screening programmes at major GCC public hospitals and growing demand for advanced molecular diagnostic testing at private hospital networks serving the expatriate population. South Africa is the most established market on the African continent for colorectal cancer diagnostics, with the National Cancer Registry and private healthcare networks supporting commercial molecular testing, while Sub-Saharan Africa represents a largely underpenetrated market where basic colorectal cancer screening infrastructure is still being developed.